CTI BioPharma Corp said on Monday the U.S. Food and Drug Administration approved its drug Vonjo (pacritinib) for treating adult patients with a type of bone marrow cancer who also have low blood platelet count.
The nod makes it the third approved drug for the disease. WTVB
